Form 4: TG Therapeutics Director Acquires Stock Tracking Units

TG Therapeutics Director Sagar Lonial acquired 8,325 Stock Tracking Units on June 11, 2026, which vest on the first anniversary of the grant date.

Summary

• Sagar Lonial, a Director at TG Therapeutics, Inc. (TGTX), acquired 8,325 Stock Tracking Units (STUs) on June 11, 2026.
• These STUs represent a contingent right to receive either one share of common stock or a cash payment equivalent to the fair market value of one share.
• The decision on whether to issue stock or cash rests with the committee administering the Issuer's 2022 Incentive Plan.
• The STUs are subject to vesting upon the first anniversary of the grant date, provided Lonial remains in continuous service with the Issuer.
• The transaction was reported on June 15, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation award to a director rather than a significant financial event or strategic shift.

Positives

• Director acquisition of equity-linked instruments can signal confidence in the company's future prospects.
• The STUs provide a potential upside for the director tied to the company's stock performance.
• The structure of the STUs allows for flexibility in how the company settles the award (stock or cash).

Negatives

• The acquisition is of Stock Tracking Units, not direct shares, meaning the benefit is contingent and not immediate ownership.
• The value of the STUs is subject to the company's stock price performance and the committee's discretion on settlement.

Risks

• The value of the Stock Tracking Units is dependent on the future performance of TG Therapeutics' stock price.
• The committee of the Board of Directors has the sole discretion to determine whether the STUs will be settled in stock or cash.
• Vesting is contingent on the reporting person remaining in continuous service with the Issuer through the vesting date.

Future Outlook

The Stock Tracking Units are set to vest on the first anniversary of the grant date, contingent on the reporting person's continued service. The settlement of these units, either in stock or cash, will occur no later than thirty days after the first anniversary of the grant date, at the discretion of the Board's committee.

Industry Context

StockSavvy.ai notes that the issuance of Stock Tracking Units is a common form of executive and director compensation in the biotechnology and pharmaceutical sectors, aligning management's interests with shareholder value through performance-based awards.

Stakeholder Impact

• Shareholders: The acquisition of STUs by a director may be viewed positively as it aligns director incentives with company performance, potentially leading to increased shareholder value if the stock price rises.
• Employees: The structure of the STUs reflects a common compensation practice, but this specific transaction directly impacts the director.
• Management: The transaction is part of the ongoing compensation and incentive structure for key personnel.

Next Steps

• Vesting of Stock Tracking Units on the first anniversary of the grant date (June 11, 2027, assuming grant date is June 11, 2026).
• Settlement of Stock Tracking Units (either in stock or cash) no later than thirty days after the first anniversary of the grant date.

Key Dates

Keywords

TG Therapeutics, TGTX, Form 4, Insider Trading, Stock Options, Equity Awards, Director Compensation, Securities Exchange Act, Stock Tracking Units